#Myeloma Paper of the Day: Response rate & EFS to 2nd line dara/bortez/dex in relapsed/refractory light chain AL #amyloidosis after initial bortez-based regime are better if prior response was CR/VGPR & if relapsed disease vs. inadequate prior response: pubmed.ncbi.nlm.nih.gov/38840512/.

Myeloma Paper of the Day, June 7th, suggested by Robert Z. Orlowski British Journal of Haematology @HelenLachmann Carol Whelan Joshua Bomsztyk oncodaily.com/insight/79343.… #Cancer #CancerResearch #Amyloidosis #OncoDaily #Oncology

DVD is an effective treatment for second line therapy in AL amyloidosis, although more limited in cases where patients had an inadequate response to front line bortezomib buff.ly/3KBzdqA @Jbomsztyk awechalekar

Long term follow up (5 years) of HOVON 104 trial is online! doi.org/10.1002/jha2.9…. This collaborative trial investigated bortezomib-dex induction before HDM and autologous SCT in newly diagnosed AL amyloidosis patients. A thread 1/8

I’m excited to share that my latest review article on AL amyloidosis is now published in the New England Journal of Medicine! BU Amyloidosis Center Boston U Chobanian & Avedisian School of Medicine Boston Medical Center Systemic Light Chain Amyloidosis | New England Journal of Medicine nejm.org/doi/pdf/10.105…

Our multicenter study led by ⁦Danai Dima⁩ ⁦Michael Hughes⁩ on Venetoclax outcomes after Dara-failure in AL #Amyloidosis: VGPR rate ~90% Cardiac Organ RR~70% ~1 in 4 required another LoT at a median f/u of 22 mo. No treatment-related deaths! tandfonline.com/doi/full/10.10…

Are you a clinician who sees patients with secondary polycythaemia? Are you frustrated by the lack of an evidence base for treating these patients? Does your practise differ from your colleagues when treating these patients?

🧵We're pleased to announce that Teclistamab (Tecvayli®) has been approved on the NHS in England and Wales today, with conversations still ongoing regarding the full scope of access to the drug: myeloma.org.uk/news/teclistam… #myeloma #MultipleMyeloma #MyelomaUK #BloodCancer 1/4

#Myeloma Paper of the Day: Extracellular volume (ECV) mapping is an independent predictor of prognosis in AL #amyloidosis, and can help define hematological response associated w/ better long-term outcomes & potentially inform treatment strategies: pubmed.ncbi.nlm.nih.gov/39167388/. #mmsm

Mass spectrometry is one of the most sensitive ways for detecting monoclonal protein in the peripheral blood. Similar to how there are different ways of detecting MRD in bone marrow (next generation sequencing or flow cytometry), there are different types of mass spec platforms

#LabourConference24 Proud to be raising awareness of heart failure #amyloidosisuk BSEcho Kidney Care UK @kidneycareuk.bsky.social British Society for Heart Failure #theFword #25in25 BSH Nurse Forum Thanks for your support again this year Wes Streeting Great to meet you Dr Zubir Ahmed MP

dFLC not independently predictive of survival in a uniformly treated patients with bortezomib. Less relevant with more effective treatment with daratumumab. awechalekar Refining prognostication in systemic AL amyloidosis: limited value of dFLC tandfonline.com/doi/full/10.10…

Lily Ebert — 1923-2024. A light that shone so brightly has today gone dark.

Come and join the team at #BSH - we are hiring for three exciting new roles! Find out more here: b-s-h.org.uk/about-us/work-…

The amazing team from UK - National amyloidosis centre Royal Free London presenting annual clinical audit - over 1300 new amyloidosis patients seen last year with patient satisfaction over 97% highly positive - a beacon for rare diseases. A huge thanks to the whole team for an

🎥 Hear about the clinical issue of hidden light chain #amyloidosis in patients with #MultipleMyeloma in an interview with Ashutosh Wechalekar (UCLH) from #EHA2025: 👉 ow.ly/Gf7j50WjzmU 👈 #MMSM #Myeloma #HemOnc

BSH are recruiting 8 new members to help shape the future of supportive care in haematology in the newly created Supportive Care SIG Committee 📍 Remote role with occasional in-person meetings 🕒 3-year term | ~2–4 hrs/month 📅 Apply by: 15 September bit.ly/3Jm1svR

At BSH, volunteers have the opportunity to drive real change, from developing education resources to shaping our voice. Interested in helping us? Explore our volunteer vacancies here: bit.ly/3Jm1svR

The BSH Workforce Project is gathering views on the vital role of liaison haematology across the UK. If you haven’t yet shared your input, there’s still time—the survey deadline has been extended to 31st August 2025. Complete the survey here:bit.ly/41emsuU

Are you a BSH member with a pioneering idea that could advance haematology? We’re offering five grants of up to £40,000 to support novel, high-impact research — whether clinical, data-driven, or community-focused. Learn more here: bit.ly/3JmBfO5